BeiGene | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

⟵ Back to Search Results

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Beigene Study ID

BGB-LC-201

ClinicalTrials.gov ID

NCT05635708

EudraCT Number

2022-502738-18-00

China Drug Trials ID

CTR20230892

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents